Research Paper|Volume 13, Issue 12|pp 16248—16266

Pan-cancer analysis reveals an immunological role and prognostic potential of PXN in human cancer

Yun Chen¹, Han Zhao^2,^3,⁴, Yan Xiao⁵, Peijun Shen^6,⁷, Li Tan¹, Shaohui Zhang¹, Qiong Liu¹, Zhengrong Gao¹, Jie Zhao¹, Yaqiong Zhao¹, Yue Guo¹, Yunzhi Feng¹

¹Department of Stomatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China
²Department of Ophthalmology, Eye, Ear, Nose, and Throat Hospital of Fudan University, Shanghai 200000, China
³Laboratory of Myopia, NHC Key Laboratory of Myopia, Fudan University, Chinese Academy of Medical Sciences, Shanghai 200000, China
⁴Shanghai Key Laboratory of Visual Impairment and Restoration, Fudan University, Shanghai 200000, China
⁵Nursing Department, Ganzhou Municipal Hospital, Gannan Medical University, Ganzhou, Jiangxi 341000, China
⁶Department of Gastroenterology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
⁷Hunan Key Laboratory of Nonresolving Inflammation and Cancer, Central South University, Changsha, Hunan 410011, China

* Equal contribution

Received: March 5, 2021Accepted: May 19, 2021Published: June 16, 2021

https://doi.org/10.18632/aging.203154

Copyright: © 2021 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Paxillin (PXN) is a protein involved in numerous physiological processes, and its presence is closely related to the occurrence and development of many types of tumors. However, no studies have analyzed PXN from a pan-cancer perspective. We analyzed PXN expression, immune cell infiltration, prognosis, and biological function across different types of tumors included in The Cancer Genome Atlas and Gene Expression Omnibus datasets. The results showed that expression of PXN varies in different tumors. Expression of PXN strongly correlated with prognosis in patients with tumors; higher PXN expression usually was linked to poor overall and disease-free survival. Expression of PXN in breast invasive carcinoma and lymphoid neoplasm diffuse large B-cell lymphoma was related to the degree of CD8+ T-cell infiltration, and infiltration of cancer-associated fibroblasts, such as kidney renal papillary cell carcinoma and brain lower-grade glioma, was also observed in other tumors. The results of pan-cancer analysis showed that abnormal PXN expression was related to poor prognosis, immune infiltration, and protein phosphorylation in different tumor types. Therefore, the PXN gene may become a potential biomarker of clinical tumor prognosis.